65 results
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
28 Mar 24
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
5:20pm
; the Company’s ability to fund development activities and achieve development goals into 2025; the Company’s ability to protect its intellectual
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
25 Mar 24
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001
4:07pm
stage trials; the Company’s ability to fund development activities and achieve development goals into 2025; the Company’s ability to protect its
8-K
EX-99.2
f64 5j8owuq0nr
25 Mar 24
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001
4:07pm
8-K
EX-99.1
vxf q1hsreq5xhg8vf
25 Mar 24
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:03pm
8-K
EX-99.1
nq70d2f0
8 Jan 24
Regulation FD Disclosure
8:09am
8-K
61gp1ijaj310vy rtn
8 Jan 24
Regulation FD Disclosure
8:09am
8-K
EX-99.1
g2nr q7r0tw83
1 Dec 23
Regulation FD Disclosure
9:04am
8-K
EX-99.1
oqfupsskvm4oge4
7 Nov 23
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:05am
SC TO-I
EX-99
r5yd3xk96cpye9ub
2 Nov 23
Issuer tender offer statement
9:01am
8-K
EX-99.1
1pk7noe4ww3 h3q
20 Sep 23
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
4:37pm
8-K
EX-99.1
jh483xgnsoyvm
7 Aug 23
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:05am
8-K
EX-99.2
u773mbibv ppb0h2vse
25 Jul 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
r65z0i9mdz38rrqbppun
25 Jul 23
Regulation FD Disclosure
7:05am